Analysis of the consumption volumes of antithrombotic drugs used for pharmacotherapy of atrial fibrillation in Saratov Region

Analysis of the consumption volumes of antithrombotic drugs used for pharmacotherapy of atrial fibrillation in Saratov Region

Objective: To study the evolution of consumption of antithrombotic drugs used for the treatment of atrial fibrillation (AF) at the outpatient stage in the Saratov Region using the ATC/DDD (Anatomical Therapeutic Chemical Classification / Defined Daily Doses) and drug utilization 90% (DU90%) analysis...

Full description

Bibliographic Details
Main Authors:	А. V. Sokolov, О. V. Reshet’ko
Format:	Article
Language:	Russian
Published:	IRBIS LLC 2022-01-01
Series:	Фармакоэкономика
Subjects:	atrial fibrillation anticoagulants antiplatelet agents consumption volumes
Online Access:	https://www.pharmacoeconomics.ru/jour/article/view/624

Similar Items

Prognostic impact of a history of cancer and atrial fibrillation in antithrombotic therapy for chronic heart failure
by: Kotaro Nochioka, et al.
Published: (2022-08-01)

ANTITHROMBOTIC THERAPY AT AN ATRIAL FIBRILLATION: OLD PROBLEMS AND NEW SOLUTIONS
by: M. Yu. Gilyarov, et al.
Published: (2016-01-01)

Practical aspects of antithrombotic therapy in patients with atrial fibrillation and coronary artery disease
by: Zh. D. Kobalava, et al.
Published: (2021-10-01)

Antithrombotic prophylaxis of atrial fibrillation in an Italian real-world setting: a retrospective study
by: Ermini G, et al.
Published: (2017-07-01)

Major determinants for the selecting antithrombotic therapies in patients with nonvalvular atrial fibrillation in Japan (JAPAF study)
by: Koichi Kusakawa, et al.
Published: (2017-04-01)

Post‐Intracranial Hemorrhage Antithrombotic Therapy in Patients With Atrial Fibrillation
by: Shin‐Yi Lin, et al.
Published: (2022-03-01)

Antithrombotic therapy for atrial fibrillation and comorbidities — how to choose the optimal solution?
by: E V Schlyakhto, et al.
Published: (2022-01-01)

Randomised trials and meta-analyses of double vs triple antithrombotic therapy for atrial fibrillation-ACS/PCI: A critical appraisal
by: Mattia Galli, et al.
Published: (2020-06-01)

Characteristics and antithrombotic treatment patterns of patients with concomitant coronary artery disease and atrial fibrillation from Thailand’s COOL-AF registry
by: Arjbordin Winijkul, et al.
Published: (2021-03-01)

Net clinical benefit of antithrombotic therapy for atrial fibrillation patients with stable coronary artery disease
by: So-Ryoung Lee, et al.
Published: (2022-08-01)

ANTITHROMBOTIC THERAPY IN ATRIAL FIBRILLATION: NEW DATA AND NEW HORIZONS
by: M. Yu. Gilyarov, et al.
Published: (2016-01-01)

PATIENTS WITH ATRIAL FIBRILLATION AND ISCHEMIC HEART DISEASE: HOSPITALIZATION STRUCTURE AND ANTITHROMBOTIC THERAPY (RECVASA AF-KURSK REGISTRY)
by: V. P. Mikhin, et al.
Published: (2017-05-01)

THE SELECTION PROBLEMS OF ANTITHROMBOTIC THERAPY IN NONVALVULAR ATRIAL FIBRILLATION WITH COMORBIDITIES
by: N. A. Koziolova, et al.
Published: (2015-08-01)

The Management of Combined Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Particularly Complex Challenge, Especially in the Elderly
by: Leonardo Bencivenga, et al.
Published: (2018-07-01)

Transcatheter Heart Valve Thrombosis in a Patient With Polycythemia Vera Despite Apixaban Therapy for Atrial Fibrillation
by: Gauranga Mahalwar, MD, et al.
Published: (2021-02-01)

ATRIAL FIBRILLATION AND HEART FAILURE: APPROACHES TO ANTITHROMBOTIC THERAPY
by: B. A. Tatarsky, et al.
Published: (2017-08-01)

Antithrombotic therapy in coronary artery disease patients with atrial fibrillation
by: Lili Wei, et al.
Published: (2020-07-01)

Dual antithrombotic therapy and gastroprotection in atrial fibrillation: an observational primary care study
by: Charis Xuan Xie, et al.
Published: (2022-12-01)

UP TO DAY POSSIBILITIES OF ATRIAL FIBRILLATION PREVENTION
by: E. A. Protasova, et al.
Published: (2015-12-01)

Antithrombotic therapy after angioplasty of pulmonary vein stenosis due to atrial fibrillation ablation: A two‐center experience and review of the literature
by: Thomas Fink, et al.
Published: (2022-12-01)

Features of pharmacotherapy and clinical course of atrial fibrillation in patients with type 2 diabetes in real clinical practice. Saratov Journal of Medical Scientific
by: Graifer l.V., et al.
Published: (2014-03-01)

Long-term prognostic significance of history of cancer and atrial fibrillation in coronary artery disease
by: Kotaro Nochioka, et al.
Published: (2023-12-01)

Antithrombotic therapy in patients with atrial fibrillation and coronary artery disease
by: Abdelmoniem Moustafa, et al.
Published: (2019-10-01)

Optimal antithrombotic therapy in ischemic stroke patients with non-valvular atrial fibrillation and atherothrombosis: study protocol for a randomized controlled trial
by: Shuhei Okazaki, et al.
Published: (2024-10-01)

Antithrombotic Therapy for Atrial Fibrillation and Coronary Artery Disease in Patients With Prior Atherothrombotic Disease: A Post Hoc Analysis of the AFIRE Trial
by: Yasushi Matsuzawa, et al.
Published: (2021-11-01)

Atrial Fibrillation and Stroke in Elderly Patients
by: Geetanjali Dang, et al.
Published: (2016-11-01)

THE APPROPRIATENESS OF ANTITHROMBOTIC THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN REAL CLINICAL PRACTICE
by: A. Y. RYCHKOV, et al.
Published: (2016-12-01)

Antiplatelet therapy is not a safer alternative to oral anticoagulants, even in older hospital-discharged patients with atrial fibrillation
by: Mario Bo, et al.
Published: (2016-10-01)

The use status of anticoagulation drugs for inpatients with nonvalvular atrial fibrillation in Southwest China
by: Zheng HJ, et al.
Published: (2017-03-01)

Efficacy and safety of various antithrombotic regimens after left atrial appendage occlusion
by: D. V. Pevsner, et al.
Published: (2022-09-01)

High Mortality Rates Among Patients With Non‐Traumatic Intracerebral Hemorrhage and Atrial Fibrillation on Antithrombotic Therapy Are Independent of the Presence of Cerebral Amyloid Angiopathy: Insights From a Population‐Based Study
by: Shiva P. Ponamgi, et al.
Published: (2020-08-01)

ANTIPLATELET THERAPY OF ATRIAL FIBRILLATION: FOCUS ON THE ELDERLY
by: E. А. Ushkalova, et al.
Published: (2017-03-01)

RISK OF THROMBOEMBOLIC COMPLICATIONS AND ANTITHROMBOTIC THERAPY IN IN-PATIENTS WITH PERMANENT AND RECURRENT ATRIAL FIBRILLATION IN REAL CLINICAL PRACTICE
by: I. V. Grajfer, et al.
Published: (2015-12-01)

Stroke prevention in atrial fibrillation changes after dabigatran availability in China: The GLORIA‐AF registry
by: Changsheng Ma, et al.
Published: (2020-06-01)

CURRENT PRINCIPLES AND TRENDS OF ATRIAL FIBRILLATION PHARMACOTHERAPY
by: Yu. A. Bunin
Published: (2016-01-01)

Changes in Antithrombotic Therapy of Atrial Fibrillation in the Hospital in 2011-2012 and 2016-2017 (Pharmacoepidemiological Analysis)
by: O. V. Reshetko, et al.
Published: (2020-11-01)

ANTITHROMBOTIC THERAPY IN ATRIAL FIBRILLATION: RECENT APPROACHES AND NEAR PERSPECTIVES
by: Ya. P. Dovgalevskiy, et al.
Published: (2016-01-01)

Approaches to anticoagulation therapy selection in patients with non-valvular atrial fibrillation and ischemic heart disease
by: N. A. Koziolova, et al.
Published: (2016-04-01)

Antithrombotic Therapy in the Prevention of Stroke
by: Shyamal Bir, et al.
Published: (2021-12-01)

Changes in Antithrombotic Therapy Prescription in Patients with a Combination of Atrial Fibrillation and Myocardial Infarction in a Specialised Inpatient Department from 2016–2019 and Associations with Prognosis
by: Sergey Stepanovich Yakushin, et al.
Published: (2023-08-01)